HBM Holdings Limited
HBMHF
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.38B
Close$
Share Statistics
| Market cap | $9.38 Billion |
|---|---|
| Enterprise Value | $9.11 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.12 |
| Beta | 1.34 |
| Outstanding Shares | 836,738,402 |
Return
| Return on Equity | 29.10% |
|---|---|
| Return on Assets | 22.80% |
| Return on Invested Capital | 24.64% |
Valuation & Multiples
| P/E Ratio | 14.07 |
|---|---|
| PEG | 17.48 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 37.35 |
| Enterprise Value to EBIT | 82.85 |
| Enterprise Value to Net Income | 74 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.22 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About HBM Holdings Limited
327 employees
CEO: Jingsong Wang HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several p...